Bayer's Cancer Therapy Slashes Risk of Spread or Death by 58 Percent

2026-10-26 companies

Leverkusen, Monday, 26 October 2026.
Adding darolutamide to standard radiation therapy cut the risk of metastasis or death by 58% in high-risk prostate cancer patients, strengthening Bayer’s high-margin oncology growth pipeline.

Bayer’s Breakthrough in Prostate Cancer Treatment

German pharmaceutical giant Bayer AG (ETR: BAYN, OTC: BAYRY) has achieved a significant milestone in oncology after presenting groundbreaking clinical trial results for its prostate cancer drug darolutamide at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid [1][2][3][4][5][6][7][8][9]. The Phase III DASL-HiCaP trial data, presented on October 24, 2026, demonstrated that adding darolutamide to standard androgen deprivation therapy (ADT) and radiation therapy reduced the risk of metastasis or death by 58% in high-risk prostate cancer patients [1][2][3][4][5][6][7][8][9]. This represents a major advancement in treating prostate cancer patients at high risk of recurrence, a group that faces significant challenges despite initial curative therapy [1][2][3][4][5][6][7][8][9].

Clinical Data Demonstrates Clear Benefit

The interim analysis of the DASL-HiCaP trial, conducted across Australia, New Zealand, Canada, the United States, Ireland, and the United Kingdom, evaluated 1,106 patients with very high-risk localized or biochemically recurrent prostate cancer [2][3][5][7][9]. At a median follow-up of 3.8 years, the combination therapy showed a hazard ratio of 0.42 (95% CI: 0.27–0.66, p=0.0001), indicating a 58% reduction in the risk of metastasis or death compared to placebo [2][3][5][7][9]. The 4-year metastasis-free survival rate reached 95% for patients receiving darolutamide versus 88% for those receiving placebo [2][3][5][7][9]. Secondary endpoints further supported these findings, with a 53% reduction in prostate-specific antigen progression-free survival (PSA-PFS) and a 4-year PSA-PFS rate of 91% versus 83% for placebo [2][3][5][7][9].

Expert Endorsement and Market Implications

Dr. Tamim Niazi, Associate Professor of Oncology at McGill University and Co-Lead Investigator of the study, emphasized the clinical significance of these results: ‘The improvement in metastasis-free survival seen in interim results from the DASL-HiCaP trial highlights the potential of adding darolutamide to standard androgen deprivation therapy and radiation therapy to help prevent or delay disease progression in patients who are at high risk of progression despite receiving primary curative therapy’ [2][3][6][8][9]. Christine Roth, Executive Vice President of Global Product Strategy and Commercialization at Bayer’s Pharmaceuticals Division, highlighted the broader implications: ‘These new data underscore the potential of darolutamide to improve outcomes for patients in the early prostate cancer setting, adding to the broad body of evidence supporting its use across different stages of the disease’ [2][6][8]. The positive clinical data comes at a critical time for Bayer, which is seeking to offset patent expirations and legal headwinds across its broader business portfolio through high-margin oncology treatments like darolutamide [1].

Pipeline Strength and Future Prospects

Darolutamide, marketed as Nubeqa™, is already approved in over 85 markets, including the U.S., EU, and China, for metastatic hormone-sensitive prostate cancer (mHSPC) and non-metastatic castration-resistant prostate cancer (nmCRPC) [2][8][9]. The drug generated €2.39 billion in sales in 2025, representing a 57% increase from the previous year, and is positioned as a key growth driver for Bayer’s pharmaceutical division [5][8]. The latest trial results could expand its use into earlier disease settings, potentially reaching more patients across the prostate cancer care continuum [2][6][8]. While the drug’s safety profile was consistent with known data, with Grade ≥3 adverse events occurring in 43% of the darolutamide group versus 36% in the placebo group, the overall benefit-risk ratio remains favorable [2][3][5][7][9]. Long-term participant follow-up is ongoing to evaluate overall survival and other secondary endpoints, with final analysis of the primary endpoint expected in 2027 [2][5][9].

Sources

Pharmaceuticals Oncology